Karyopharm Therapeutics Inc (KPTI)

Currency in USD
5.920
+1.270(+27.31%)
Closed·
5.700-0.220(-3.72%)
·

KPTI Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-4.32 / -0.1025
Revenue / Forecast
37.93M / 41.73M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/2025-4.32/-0.10337.93M/41.73M-4,114.63%-9.11%Free Sign Up
03/2025-2.77/-0.2630.02M/37.84M-965.38%-20.67%Free Sign Up
12/2024-0.24/-0.2530.54M/38.2M+4%-20.05%Free Sign Up
09/2024-0.26/-0.2638.8M/38.12M0%+1.78%Free Sign Up
06/2024-0.2/-0.3142.8M/36.21M+35.48%+18.2%Free Sign Up
03/2024-0.32/-0.3333.1M/35.86M+3.03%-7.7%Free Sign Up
12/2023-0.36/-0.3633.75M/33.75M0%0%Free Sign Up
09/2023-0.3/-0.2836M/37.27M-7.14%-3.41%Free Sign Up
06/2023-0.29/-0.3437.6M/35.67M+14.71%+5.41%Free Sign Up
03/2023-0.3/-0.3738.7M/36.3M+18.92%+6.61%Free Sign Up

All numbers in USD

Karyopharm Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 revenue declined to $37.9M from $42.8M YoY, despite 6% growth in XPOVIO sales; net loss of $37.3M or $4.32 per share
  • 20% workforce reduction announced to optimize costs; exploring strategic alternatives to address liquidity concerns with debt maturity in October 2025
  • Full-year 2025 revenue guidance of $140M-$155M; XPOVIO net product revenue expected between $110M-$120M
  • Three major data readouts anticipated in 2026 for pipeline advancements in myelofibrosis and endometrial cancer
  • Cash and equivalents down to $52M from $109.1M at end of 2024; financial health score of 1.92/5, labeled as 'FAIR' by analysts
Last Updated: 11/08/2025, 14:26
Read Full Transcript

FAQ

What Is Karyopharm's Earnings Per Share (TTM)?

The Karyopharm EPS (TTM) is -14.62.

What Is Karyopharm’s Revenue Forecasts For Upcoming Quarters?

Karyopharm’s revenue forecast is 41.76M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.